[go: up one dir, main page]

HK1084015A1 - Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives - Google Patents

Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives Download PDF

Info

Publication number
HK1084015A1
HK1084015A1 HK06103919.6A HK06103919A HK1084015A1 HK 1084015 A1 HK1084015 A1 HK 1084015A1 HK 06103919 A HK06103919 A HK 06103919A HK 1084015 A1 HK1084015 A1 HK 1084015A1
Authority
HK
Hong Kong
Prior art keywords
composition
weight
composition according
derivative
intimate admixture
Prior art date
Application number
HK06103919.6A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1084015B (en
Inventor
Ruth Tenengauzer
Julia Hrakovsky
Original Assignee
Teva Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Limited filed Critical Teva Pharmaceutical Industries Limited
Publication of HK1084015A1 publication Critical patent/HK1084015A1/en
Publication of HK1084015B publication Critical patent/HK1084015B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06103919.6A 2003-06-26 2004-06-24 Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives HK1084015B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48251803P 2003-06-26 2003-06-26
US60/482,518 2003-06-26
PCT/US2004/020484 WO2005002548A1 (en) 2003-06-26 2004-06-24 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives

Publications (2)

Publication Number Publication Date
HK1084015A1 true HK1084015A1 (en) 2006-07-21
HK1084015B HK1084015B (en) 2009-07-24

Family

ID=

Also Published As

Publication number Publication date
EP1635792B1 (en) 2009-03-04
ATE424192T1 (de) 2009-03-15
CA2530788A1 (en) 2005-01-13
MXPA06000226A (es) 2006-03-21
ES2322854T3 (es) 2009-06-30
EP1635792A1 (en) 2006-03-22
US20050069586A1 (en) 2005-03-31
PL1635792T3 (pl) 2009-08-31
US20070212409A1 (en) 2007-09-13
CA2530788C (en) 2010-02-09
IL172602A0 (en) 2006-04-10
DK1635792T3 (da) 2009-06-15
PT1635792E (pt) 2009-05-15
DE602004019777D1 (de) 2009-04-16
WO2005002548A1 (en) 2005-01-13
US20080058404A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
US20080058404A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives
EP2054040B1 (en) Method for making solid dispersions of midostaurin
EP1334720B1 (en) Nateglinide-containing preparations
CN104771364A (zh) 固体组合物
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
CA2732777A1 (en) Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20080008751A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20220387418A1 (en) Pharmaceutical compositions of cabozantinib
HUT73657A (en) Compositions in the form of solid solutions, containing coumarin derivatives
US20080015188A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
HK1084015B (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3-carboxylic acid derivatives
EP1864677B1 (en) Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof
EP1889629B1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
WO2015199115A1 (ja) 経口投与用医薬組成物
KR100484994B1 (ko) 약학조성물
CA3160393A1 (en) A pharmaceutical oral dosage form of q203
CA2659814A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
HK1116684A (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
HK1117419A (en) Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130624